Abstract
Metabolomics is of the increasing interests in medical research and the study of respiratory diseases. This novel type of small molecule analysis can be performed not only on conventional biological samples such as plasma or urine but also on sputum, bronchoalveolar fluid, exhaled breath condensate or exhaled breath itself (which is particularly relevant for research on respiratory diseases). On one hand, powerful analytical methodologies (including mass spectrometry and nuclear magnetic resonance spectroscopy) are labour-intensive but enable the exhaustive identification of metabolites. On the other hand, electronic noses can be used for exhaled breath analysis. Although the latter devices do not contain metabolite-specific sensors, they produce a condition- or treatment-specific “breathprint” based on pattern recognition. Breath analysis with electronic noses is noninvasive, and can be performed at the bedside in real time. Here, we review the literature on metabolomics studies in respiratory medicine, with a focus on the evaluation of responses to pharmacotherapy.
Keywords: Metabolomics, volatolomics, lung disease, electronic nose.
Current Pharmaceutical Design
Title:Metabolomics in the Diagnosis and Pharmacotherapy of Lung Diseases
Volume: 23 Issue: 14
Author(s): Philippe Devillier, Helene Salvator, Emmanuel Naline, Louis-Jean Couderc and Stanislas Grassin-Delyle*
Affiliation:
- INSERM UMR1173, UFR Sciences de la Santé Simone Veil, Université Versailles Saint Quentin en Yvelines, Université Paris Saclay, 2, avenue de la source de la Bièvre, F- 78180 Montigny-le-Bretonneux,France
Keywords: Metabolomics, volatolomics, lung disease, electronic nose.
Abstract: Metabolomics is of the increasing interests in medical research and the study of respiratory diseases. This novel type of small molecule analysis can be performed not only on conventional biological samples such as plasma or urine but also on sputum, bronchoalveolar fluid, exhaled breath condensate or exhaled breath itself (which is particularly relevant for research on respiratory diseases). On one hand, powerful analytical methodologies (including mass spectrometry and nuclear magnetic resonance spectroscopy) are labour-intensive but enable the exhaustive identification of metabolites. On the other hand, electronic noses can be used for exhaled breath analysis. Although the latter devices do not contain metabolite-specific sensors, they produce a condition- or treatment-specific “breathprint” based on pattern recognition. Breath analysis with electronic noses is noninvasive, and can be performed at the bedside in real time. Here, we review the literature on metabolomics studies in respiratory medicine, with a focus on the evaluation of responses to pharmacotherapy.
Export Options
About this article
Cite this article as:
Devillier Philippe, Salvator Helene, Naline Emmanuel, Couderc Louis-Jean and Grassin-Delyle Stanislas*, Metabolomics in the Diagnosis and Pharmacotherapy of Lung Diseases, Current Pharmaceutical Design 2017; 23 (14) . https://dx.doi.org/10.2174/1381612823666170130155627
DOI https://dx.doi.org/10.2174/1381612823666170130155627 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Fractalkine (CX3CL1) in Regulating Neuron-Microglia Interactions: Development of Viral-Based CX3CR1 Antagonists
Current Alzheimer Research PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Cancer Diagnosis and Treatment Guidance: Role of MRI and MRI Probes in the Era of Molecular Imaging
Current Pharmaceutical Biotechnology Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Preface
Current Cancer Drug Targets Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Functional Role of miR-34 Family in Human Cancer
Current Drug Targets Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets Design and Development of Molecular Imaging Probes
Current Topics in Medicinal Chemistry FTD and ALS: A Tale of Two Diseases
Current Alzheimer Research Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design Role of Apoptosis and Proinflammatory Cytokines in Influenza Virus Morbidity and Mortality
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design The Role of Flavonoids in Inhibiting IL-6 and Inflammatory Arthritis
Current Topics in Medicinal Chemistry Synthetic and Natural Coumarins as Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Current Molecular Pharmacology Activation of p53 by Specific Agents in Potential Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology